Ignite Creation Date:
2024-05-06 @ 3:55 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02402660
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2015-03-09
Brief Title:
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Sponsor:
Alkeus Pharmaceuticals Inc
Organization:
Alkeus Pharmaceuticals Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Autosomal Recessive Stargardt Disease 1 ABCA4-related |
| Stargardt Disease |
| Stargardt Macular Degeneration |
| Stargardt Macular Dystrophy |
Keywords: